Risk Factors for Major Adverse Cardiovascular Events, Malignancies, and Serious Infections With Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of a 3‐Year J‐Post‐Marketing SurveillanceKunihiro Yamaoka, Toshitaka Hirano|International Journal of Rheumatic Diseases|2026Cited by 1